Find Nephrology Clinical Drug Pipeline Developments & Deals

Lead Product(s): DM199

Therapeutic Area: Nephrology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

WI facility to support the trial using its GPEx cell line development technology. DiaMedica intends to initiate enrollment in the study in the next few weeks.

Lead Product(s): Atrasentan Hydrochloride

Therapeutic Area: Nephrology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Chinook Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 10, 2020

Details:

Chinook Therapeutics in-license of atrasentan provides a unique opportunity for Chinook to add a potential new drug to its precision medicine portfolio for the treatment of rare CKD conditions.

Lead Product(s): Undisclosed

Therapeutic Area: Nephrology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: DCVC Bio

Deal Size: $33.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 07, 2020

Details:

The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.